Skip to main content
Springer logoLink to Springer
. 2021 May 26;64(8):1900–1901. doi: 10.1007/s00125-021-05460-0

Correction to: Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled study

Linong Ji 1,, Ying Du 2, Min Xu 2, Xiangjun Zhou 2, Zhaohui Mo 3, Jianhua Ma 4, Jiarui Li 5, Yufeng Li 6, Jingna Lin 7, Yanjun Wang 8, Jing Yang 9, Weihong Song 10, Hui Jin 11, Shuguang Pang 12, Hui Liu 13, Ping Li 14, Jie Liu 15, Minxiu Yao 16, Wenhui Li 17, Xiaohong Jiang 18, Feixia Shen 19, Houfa Geng 20, Haifeng Zhou 21, Jianmin Ran 22, Minxiang Lei 23, Yinghong Du 24, Shandong Ye 25, Qingbo Guan 26, Wenshan Lv 27, Huiwen Tan 28, Tao Chen 28, Jinkui Yang 29, Guijun Qin 30, Shiyun Li 31, Lei Chen 32
PMCID: PMC8496613  PMID: 34037812

Correction to: Diabetologia

10.1007/s00125-021-05392-9

The following sentence in the Discussion was inappropriately changed to a definite statement during editing: ‘Considering the mechanism of action of PB-119, which is similar to exenatide QW, PB-119 also showed superior efficacy compared with available OADs.’

The journal would like to revert back to the authors’ original phrasing as follows:

‘Considering the mechanism of action of PB-119, which is similar to exenatide QW, PB-119 could also reveal superior efficacy in comparison with available OADs.’

The original article has been corrected.

Footnotes

The online version of the original article can be found at 10.1007/s00125-021-05392-9

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Articles from Diabetologia are provided here courtesy of Springer

RESOURCES